Verastem, Inc.
AVMAPKI FAKZYNJA CO-PACK
KRAS mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on AVMAPKI FAKZYNJA CO-PACK for KRAS mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“the Company anticipates the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026”